Tags: Drug.

Trabectedin (also known as ecteinascidin 743 or ET-743) is an anti-tumor drug. It is sold by Zeltia and Johnson and Johnson under the brand name Yondelis. It is approved for use in Europe Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials for the treatment of breast prostate and paediatric sarcomas. The European Commission and the U.S.

Trabectedin_.png
ATC prefix
L01
ATC suffix
CX01
CAS number
114899-77-3
DrugBank
DB05109
FDA UNII code
ID0YZQ2TCP
IUPAC name
(1R6R6aR7R13S14S16R)-6'814-trihydroxy-7'9-dimethoxy-41023-trimethyl-19-oxo-3'4'6712131416-octahydrospiro[616-(epithiopropano-oxymethano)-713-imino-6aH-13-dioxolo[78]isoquino[32-b][3]benzazocine-201'(2H)-isoquinolin]-5-yl acetate
PubChem
108150

Loading...

This page contains content from the copyrighted Wikipedia article "Trabectedin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.